AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 OCT 9 - (NewsRx.com & NewsRx.net) -- A British biotechnology company has reported "encouraging" results from an early-stage trial of its smallpox vaccine.
Acambis PLC compared its ACAM1000 vaccine and the vaccine widely used during the worldwide eradication program, Dryvax.
In the trial, 30 people were given a standard dose of Dryvax and the other 30 people were given an equivalent dose of ACAM1000.
Within 10 days of vaccination, all of the people who received the ACAM1000 vaccine reported a "take," the pock-mark on the skin that indicates immunity to the disease,
All except one of the Dryvax-treated subjects had successful results. The size and appearance of the "takes" were identical for both treatments.
Patients injected with the ACAM1000 vaccine reported no serious or unexpected side effects, but one subject in the Dryvax group developed a nonhealing pock-mark at the ...
Source: HighBeam Research, Early vaccine results encouraging.(Brief Article)